MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Purchases 46,620 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero purchased 46,620 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was bought at an average price of $1.35 per share, with a total value of $62,937.00. Following the completion of the transaction, the director directly owned 735,701 shares of the company’s stock, valued at approximately $993,196.35. This represents a 6.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Thursday, August 27th, Ramiro Guerrero purchased 78,239 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $1.39 per share, with a total value of $108,752.21.
• On Wednesday, August 26th, Ramiro Guerrero acquired 8,931 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.39 per share, for a total transaction of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The shares were bought at an average cost of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero bought 11,899 shares of MAIA Biotechnology stock. The stock was bought at an average price of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Trading Down 0.8%

NYSEAMERICAN:MAIA traded down $0.01 during trading hours on Tuesday, hitting $1.30. The company had a trading volume of 304,095 shares, compared to its average volume of 791,682. MAIA Biotechnology, Inc. has a 1 year low of $0.87 and a 1 year high of $3.19. The company has a market cap of $79.08 million, a P/E ratio of -2.10 and a beta of 0.24. The company has a 50-day moving average of $1.37 and a 200 day moving average of $1.44.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts forecast that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.

Hedge Funds Weigh In On MAIA Biotechnology

A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after purchasing an additional 7,746 shares during the last quarter. Centric Wealth Management increased its holdings in shares of MAIA Biotechnology by 2.0% during the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after buying an additional 11,500 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of MAIA Biotechnology during the 2nd quarter worth approximately $29,000. Jane Street Group LLC purchased a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at approximately $52,000. Finally, PVG Asset Management Corp purchased a new stake in shares of MAIA Biotechnology during the 1st quarter valued at approximately $46,000. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.